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Background: The classic light transmittance aggregometry has been regarded as gold standard of platelet function test. However, it is labor-
intensive and requires lengthy centrifugation to produce platelet rich plasma. To overcome this problem, several comercial point-of-care platelet 
function assays have been introduced for rapid evaluation of the individual response to antiplatelet therapy. Among these assays, ultegra RPFA 
(VerifyNow®) and multiple electrode platelet aggregometry (MEA, Multiplatelet analyzer®) are currently available in Korea. However, distribution of 
post-treatment platelet reactivity assessed by each test in Asians is not well known..
Methods: A total of 82 consecutive patients with DES implantation were enrolled (mean age 63±12.5,male 46%,diabetes mellitus 32%). At least 
12 hours before PCI in both groups, 300 mg of aspirin was administered orally, if not administered before, followed by oral administration of 100mg/
day. In addition to aspirin, a loading dose of 300mg, and maintenance dose of 75mg/day of clopidogrel were given, but if administration before, 
maintainance dose only. And At the day of discharge, VerifyNow® and Multiplate® assay were done. In Ultegra RFPA, aspirin reaction unit (ARU) and 
the P2Y12 reaction unit(PRU) was measured, in MEA, platelet aggregation induced by 20 &#371;l-ADP,ArA(ASPI),TRAP were measured.
Results: In Ultegra RPFA, mean ARU,PRU values were 421.90(±5.781),247.71(±10.458). In MEA, mean ADP,ArA,TRAP-induced aggregation 
unit level were 26.74(±2.257),5.39(±0.665),84.78(±3.154). The ADP-induced aggregation unit showed weak correlations with VerifyNow-PRU 
values(r=0.406,p<0.001,Kendall tau_b-0.342). And also weak relationship was found between ARU and 20ul-ArA(ASPI)-induce aggregation 
unit(r=0.297, p<0.008,Kendall tau_b-0.242).
Conclusions: Patients who underwent DES implantation showed wide variability in post-treatment platelet reactivity assessed by two kinds of 
point-of -care platelet function analysis. These two assays have poor correlation and further studies are needed to validate popular use of these 
assays to guide antiplatelet therapy in clinical practice.
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